Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges . In the US alone, AD prevalence is expected to increase from 6.5

Development 52

Development In-Vivo Compound Screening Clinical Development 52

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

Drug Discovery World

APRIL 3, 2023

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. Additionally, the intractability of some targets with alternative ligand technologies means ligands simply cannot be developed to some targets, such as toxic or non-immunogenic targets.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

World of DTC Marketing

JANUARY 31, 2021

I always have pointed instances in which pharma puts Wall Street first and patients second. Here are some of her key points from the report: 1ne: In just 10 years, the number of large, international pharmaceutical companies decreased six-fold,from60 to only 10. In pharma R&D returns have declined to 1.8 percent from 2018.

In-Vivo 187

In-Vivo Generic Drugs Gene Therapy Drugs 187

Pharmaceutical Technology

MAY 24, 2023

Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. Allogeneic therapies begin with healthy donor samples to develop the eventual therapeutic product which can be administered to multiple patients.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Drug Discovery World

JANUARY 24, 2024

Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. This has hindered development of drugs so that, from a therapeutic intervention point of view, fibrosis research is still in its infancy.

Research 59

Research Gene Expression Drugs Development 59

The Pharma Data

NOVEMBER 10, 2020

This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing. By giving companies full control of their studies, they are able to significantly speed up timelines,” Tessier said. Photo courtesy of Mispro.

Marketing 52

Marketing In-Vivo Scientist Research 52

Drug Discovery World

NOVEMBER 15, 2022

Known for its ability to offer precision and flexibility while expanding the experimental scale, synthetic biology tools can reduce development timelines and costs, and lend a competitive advantage over traditional methods. . Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

OCTOBER 1, 2020

To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. Motivations for Transition.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. All jobs have been maintained and the workforce has grown from about 220 to 350.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

Pharmaceutical Technology

APRIL 12, 2023

In February, Massachusetts-based Charles River Laboratories, the second-largest importer of nonhuman primates into the US, was served a subpoena by the US Department of Justice regarding the company’s import of wild long-tailed macaques from Cambodia. This was part of an investigation into an international primate smuggling ring.

Regulation 245

Regulation Vaccination Vaccine Medicine 245